Common TitleHPTN 083
Official Title A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men
Phase Phase III
ClinicalTrials.gov NCT02720094
Treatments
Cabotegravir
Cabotegravir
Tradename:ApretudeOther Names:Injectable cabotegravir, Long-acting injectable cabotegravirClass:Integrase Inhibitors (INSTI)Categories PREP
Funding
IndustryViiV Healthcare
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
- Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.